Debt to Equity Ratio Chart

View Debt to Equity Ratio for ALKS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Debt to Equity Ratio Chart
Start Trial

Historical Debt to Equity Ratio Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 0.8695
March 31, 2026 0.903
December 31, 2025 0.0385
September 30, 2025 0.0413
June 30, 2025 0.0447
March 31, 2025 0.049
December 31, 2024 0.0516
September 30, 2024 0.2833
June 30, 2024 0.2866
March 31, 2024 0.295
December 31, 2023 0.3095
September 30, 2023 0.284
June 30, 2023 0.3042
March 31, 2023 0.3919
December 31, 2022 0.3635
September 30, 2022 0.3887
June 30, 2022 0.3791
March 31, 2022 0.3862
December 31, 2021 0.3741
September 30, 2021 0.383
June 30, 2021 0.3867
March 31, 2021 0.4082
December 31, 2020 0.3844
September 30, 2020 0.3556
June 30, 2020 0.368
Date Value
March 31, 2020 0.3708
December 31, 2019 0.268
September 30, 2019 0.2743
June 30, 2019 0.2711
March 31, 2019 0.2709
December 31, 2018 0.2385
September 30, 2018 0.2432
June 30, 2018 0.2421
March 31, 2018 0.243
December 31, 2017 0.234
September 30, 2017 0.2375
June 30, 2017 0.2351
March 31, 2017 0.2327
December 31, 2016 0.2345
September 30, 2016 0.2361
June 30, 2016 0.2791
March 31, 2016 0.2755
December 31, 2015 0.2663
September 30, 2015 0.2584
June 30, 2015 0.2536
March 31, 2015 0.2509
December 31, 2014 0.2563
September 30, 2014 0.2696
June 30, 2014 0.2671
March 31, 2014 0.2708

Debt to Equity Ratio Definition

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

View Debt to Equity Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Debt to Equity Ratio Benchmarks

View Debt to Equity Ratio Benchmarks
Start Trial
Amarin Corp. Plc 0.0118
Jazz Pharmaceuticals Plc 0.9183
Prothena Corp. Plc 0.0244
ACADIA Pharmaceuticals, Inc. 0.0565
Biogen, Inc. 0.4433